Clinical Trial Update: Trial of HQK-1001 in Beta Thalassemia Intermedia in Lebanon [Phase 2]

View source ↗

Summary

Phase 2 trial of HQK-1001 for Beta-thalassemia intermedia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Beta-thalassemia Intermedia

Drugs mentioned

• HQK-1001

Snippet

Sponsor: Boston University | Conditions: Beta Thalassemia Intermedia | Phase 2 | Status: COMPLETED